Cell Therapies and Xellera Therapeutics Enter into a Strategic Partnership to Fast-Track Access to Cell and Gene Therapies across APAC.
Cell Therapies and Xellera Therapeutics Forge Partnership: Signing a Memorandum of Understanding (MoU) to accelerate the development and accessibility of life-changing cell and gene therapies across the Asia-Pacific region. This partnership will offer new possibilities for patients and healthcare systems alike, and transform patient care across the region with enhanced GMP capabilities and collaborative innovation.
Today, Cell Therapies Pty Ltd. and Xellera Holdings Limited (Xellera Therapeutics) have signed a Memorandum of Understanding (MoU) to advance cell and gene therapy (CGT) development and accessibility in the Asia-Pacific region.
This partnership will focus on expanding CGT access in Australia and Hong Kong. The collaboration will leverage both parties’ advanced GMP manufacturing capabilities and capacity for clinical trial and commercial supply to enable streamlined access to Asia-Pacific markets.
By addressing region-specific regulatory challenges and fostering capacity-building through joint training programs and knowledge exchange, the partnership will strengthen the regional infrastructure for advanced therapies. Through the integration of expertise and resources, both companies are committed to driving innovation and making CGT treatments more widely accessible to patients across the Asia-Pacific region.
CEO QUOTES:
CELL THERAPIES: Bev Menner, Cell Therapies CEO
“This partnership marks an important step forward in advanced the manufacturing of cell and gene therapies to supply the Asia-Pacific region,” said Bev Menner, CEO of Cell Therapies. “By combining our expertise and capabilities with Xellera, we aim to provide streamlined and secure access to both the Australian and Hong Kong markets to accelerate market expansion, offer advanced GMP manufacturing solutions, and address the unique challenges of the region. Together, we are committed to building the infrastructure and collaborations needed to make innovative therapies more accessible to patients who need them.”
XELLERA: Camie Chan, Xellera CEO
“We are thrilled to partner with Cell Therapies to improve CGT accessibility in the Asia-Pacific region. This collaboration embodies our mutual vision of enhancing CGT manufacturing capabilities and achieving regulatory harmonization. By working together, we can facilitate a quicker, more efficient transformation of advanced therapies, ultimately benefiting patients and promoting global health advancements. Moreover, we are dedicated to establishing standardized practices for CGT manufacturing in the region, ensuring the highest quality, safety, and regulatory compliance.”
